A Phase 4 interventional study of instillation of NOV03 in Dry Eye Disease (DED), sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. — 1 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Bausch Health Companies Inc..
Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 4, and was the 18th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 6 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 112 across the 24 interventional studies, 25 across the 1 observational. Of the 21 that completed or were terminated, 16 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
1 of the studies in Dry Eye Syndromes by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07778888Bausch & Lomb IncorporatedBL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General/Ocular Inclusion Criteria
1. Will be at least 18 years of age at the time of consent. 2. Able to provide written voluntary . 3. Have a subject-reported history of DED in both eyes for at least 6 months prior to Visit 1. 4. Have Tear film break-up time (TFBUT) ≤5 sec at Visit
Exclusion Criteria:
General/Ocular Exclusion Criteria
Have any ocular surface slit-lamp findings at Visit 1 and Visit 2 and/or in the opinion of the Investigator had any findings that may have interfered with trial parameters, including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: instillation of NOV03
This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
Thickness of the Mucus-aqueous Tear Film Layer
Thickness of the mucus-aqueous layer of the tear film, measured in nanometers
Time frame: over 4 hours following instillation of NOV03
Thinning Rate of the Mucus-aqueous Tear Film Layer
The rate of change in the thickness of the tear film mucus-aqueous layer, measured in nanometers/second
Time frame: over 4 hours following instillation of NOV03
| Milestone | Perfluorohexyloctane |
|---|---|
| Started | 33 |
| Completed | 27 |
| Not completed | 6 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawal by subject | 2 |
Thickness of the mucus-aqueous layer of the tear film, measured in nanometers
| nm | Perfluorohexyloctane |
|---|---|
| Thickness of the Mucus-aqueous Tear Film Layer | 3920.3 ± 797.7 |
The rate of change in the thickness of the tear film mucus-aqueous layer, measured in nanometers/second
| nm/s | Perfluorohexyloctane |
|---|---|
| Thinning Rate of the Mucus-aqueous Tear Film Layer | -62.3 ± 90.9 |
Collected over Assessed for the entire study; Visit 1 Screening through Visit 2, an average of 2 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Perfluorohexyloctane | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Age, Continuous(years) | Perfluorohexyloctane |
|---|---|
| Mean | 63.2 ± 8.7 |
| Sex: Female, Male(Participants) | Perfluorohexyloctane |
|---|---|
| Female | 2 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Perfluorohexyloctane |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Perfluorohexyloctane |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 11 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Perfluorohexyloctane |
|---|---|
| United States | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2023 to primary completion in Dec 2023, 4 months.
Results were first posted in Jul 2025, 1 year 6 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 4 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.